about
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerMeta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.The current practice, preparedness and educational preparation of oncology professionals to provide spiritual care.Returning to work following curative chemotherapy: a qualitative study of return to work barriers and preferences for intervention.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.Very high GFR in cancer patients undergoing chemotherapy: prevalence, carboplatin dosing patterns and chemotherapy toxicity.Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers.Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer.Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Pregnancy screening prior to chemotherapy administration.Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.Infliximab for ipilimumab-induced colitis: A series of 13 patients.A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing.Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.A Pilot Study of Self-Management-based Nutrition and Physical Activity Intervention in Cancer Survivors.Prostate cancer in men aged less than 50 years at diagnosis.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Acrokeratosis paraneoplastica (Bazex syndrome) associated with metastatic cutaneous squamous cell carcinoma.Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.Abiraterone in metastatic prostate cancer.Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.Is self-management feasible and acceptable for addressing nutrition and physical activity needs of cancer survivors?Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.Online information and support needs of women with advanced breast cancer: a qualitative analysis.Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.Delayed onset of benign pleural effusion following concurrent chemoradiotherapy for inoperable non-small-cell lung cancer.Serum vitamin D decreases during chemotherapy: an Australian prospective cohort studyCompeting Risks in Older Patients With Cancer: A Systematic Review of Geriatric Oncology TrialsResults of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyEarly stage ovarian cancers: angiogenesis inhibition and clear cell cancersThe emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugsInformed decision making about prostate cancer screening
P50
Q27027648-3B449ADD-3225-472B-A059-F3875EDD40E5Q27853329-95DBF79E-14E5-4D52-9746-2B0C54EF5CBAQ30151504-39B3F482-E7C5-4A4A-B313-829E57A546C8Q30209236-8ABB5571-CDEE-45B7-ABA3-D7A44CC1A3C8Q31102468-C39E24B5-3B60-4AC5-B50E-8CDD8940E154Q37249312-374746E5-9888-42F3-B24F-3C24A9205941Q37925135-2CA9625E-E23C-41E1-88FB-536CBB72AD76Q38187578-CCBD876F-5420-4C1B-B010-961303EF2F4FQ38239192-EB9DF59F-CE19-4975-82FF-B279DD907CE4Q38262334-8F7EB4E3-BCF9-4699-B117-B0DCD9323504Q38262335-0CCABC61-79AC-4BC0-9D8E-1B6F49A3A355Q38844210-793CB501-6121-453C-9CAF-AF7C9F76ED59Q38919028-3158901A-0D46-412C-BC73-71901F9080F1Q38937228-DEDA12EF-5B89-49CB-A82B-6EBF45505C84Q38979380-5F2F6C73-2CC5-401D-ABF5-4A57FA3314E5Q39033152-5BBDA3D6-5647-4C17-A3A3-7F47FB21F11CQ39040949-9D32B95B-C7AA-4D4F-8CE5-54DAEB290789Q39493255-F2A1A965-DBEF-4E94-85EE-5125FF03BF7EQ39953290-8F0E4502-1464-4F4B-83E9-101D5F6EB489Q40755853-DBE5F22F-0512-44B1-A3F4-2F0D6BD474E9Q40803697-38A8C3FE-109E-4598-BD4C-C5EC97FDEC7EQ41035635-CA3ABDD9-8624-4472-8F04-7BA13ADC60CAQ41899044-A86FA1FD-D908-4CA7-A5FE-3FA35B478DD2Q42488109-0C873B7F-13A4-4B66-8EE2-776F10AA87A1Q43099387-C2B1DBD3-34F1-4F6C-94E0-1AABAC6B7262Q44435533-ED5B0356-F307-4E33-B028-32E496DA0F25Q44630842-3F51E032-69E1-4789-9DAA-3CB18AB82FC3Q45393978-C14F7106-1A91-4C21-A22C-327C203A12FCQ45719835-35F0A6DF-33F8-480F-918F-D538B96446E1Q48055010-C1D53E73-9B01-4E32-B095-6E5517D70D2EQ48175528-8E1EE5E9-FD1D-49D6-B607-DA11631007ACQ52564370-6A897E2D-2D68-4C87-9AE3-A3A8F81615D2Q52617483-ED5C08EB-4AAA-41BF-B013-484F33DE4611Q53619871-F80DE1ED-B466-480F-A130-E2316F3D0D68Q57148906-A3FF2BBA-FDE5-421A-9F15-7FC755CC779CQ57172784-17E18BDC-FCF2-4575-94B4-AD5929F66A67Q58828834-5AD02333-0F33-4A3A-A26D-31C127E4EE92Q84775881-7C36F4D5-D5B8-4BF4-996F-27E77F95551AQ84970048-388719C7-F792-4BA4-82C4-619B789D6764Q86937471-69294DE1-368D-4C72-9865-0A75E2025B98
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ganessan Kichenadasse
@ast
Ganessan Kichenadasse
@en
Ganessan Kichenadasse
@es
Ganessan Kichenadasse
@sl
type
label
Ganessan Kichenadasse
@ast
Ganessan Kichenadasse
@en
Ganessan Kichenadasse
@es
Ganessan Kichenadasse
@sl
prefLabel
Ganessan Kichenadasse
@ast
Ganessan Kichenadasse
@en
Ganessan Kichenadasse
@es
Ganessan Kichenadasse
@sl
P106
P31
P496
0000-0001-9923-5149